NR ATOA
AU Otto,M.; Zirk,A.; Cepek,L.; Irle,E.; Pergande,G.; Ellers-Lenz,B.; Windl,O.; Kretzschmar,H.A.; Prange,H.; Mollenhauer,B.
TI Flupirtine and Dapsone on Cognitive Function in Patients with CJD
QU International Conference - Prion 2005: Between fundamentals and society's needs - 19.10.-21.10.2005, Congress Center Düsseldorf - Poster Session: Human prions, risk of blood products, and therapy HUMAN-24
PT Konferenz-Poster
AB
Background: In cell culture experiments, flupirtine maleate (FLU), a triaminopyridine compound, was able to protect neuronal cells from apoptotic cell death induced by prion protein fragments. In a double-blind study flupirtine was able to delay progression of cognitive changes for a short time. In one study dapsone was shown to delay onset of symptoms of infected animals.
Methods: Twenty-eight patients with CJD were randomized to an oral treatment with either FLU (n=13) or matching placebo (PLA; n=15). For inclusion and continuing the study the patients had to achieve at least 50% in two of the sub-scales of the dementia tests employed. A battery of standardized questionnaires was employed to monitor the progression of the disease. The main outcome variable was the cognitive part of the Alzheimer's disease assessment scale (ADAScog); the difference between baseline (BL) and the best score under treatment was defined as the primary efficacy variable for hypothesis testing. These results were compared to eight patients who were treated with a combination of FLU and dapsone according to the same protocol.
Results and Discussion: CJD types were homogeneously distributed among the treatment groups. Patients treated with FLU showed significantly less deterioration in the dementia tests than patients treated with PLA. The mean change in ADAScog (BL to best) was +8.4 (±15.3) in the FLU group and +20.6 (±15.1) in the PLA group (p = 0.02, 1-sided t-test). Patients who were treated with a combination of dapsone and FLU did also worsen. Results will be presented and discussed.
AD M.Otto, A.Zirk, L.Cepek, H.Prange, B.Mollenhauer, Department of Neurology, University of Göttingen, Germany; E.Irle, Department of Psychiatry, University Göttingen, Germany; G.Pergande, ASTA Medica AG since 1.11.01 Baxter Oncology GmbH, Frankfurt/Main, Germany; B.Ellers-Lenz, VIATRIS GmbH & Co. KG, Frankfurt/Main, since 1.3.03 Omega Mediation, Offenbach. Germany; O.Windl, Veterinary Laboratories Agency - Weybridge, United Kindom; H.A.Kretzschmar, Institute of Neuropathology, University Munich, Germany
SP englisch
PO Deutschland